Heil EL, McCreary EK. REVISITing treatment of metallo-β-lactamases. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00561-9—In this Comment, two corrections have been made. The correct treatment difference for clinical cure rate at the test-of-cure visit is 2·7% (95% CI –6·6 to 12·4). The loading dose for aztreonam–avibactam was clarified to state it was how the drug was administered in the REVISIT trial. These corrections have been made to the online version as of Nov 6, 2024, and the printed version will be correct..

中文翻译：

---

对柳叶刀感染疾病 2024 的更正;10 月 7 日在线发布。https://doi.org/10.1016/S1473-3099（24）00561-9


Heil EL，McCreary EK。重新审视金属内酰胺酶的处理 β-内酰胺酶。柳叶刀感染疾病 2024;10 月 7 日在线发布。https://doi.org/10.1016/S1473-3099（24）00561-9—在此评论中，进行了两项更正。治愈测试访视时临床治愈率的正确治疗差异为 2·7%（95% CI -6·6 至 12·4）。阐明了氨曲南-阿维巴坦的负荷剂量，以说明这是 REVISIT 试验中药物的给药方式。这些更正已对在线版本截至2024年11月6日进行了修改，打印版本将是正确的。